Skip to search formSkip to main contentSkip to account menu

CHVmP-VB protocol

Known as: BLEO/CTX/DOX/PRED/VCR/VM-26, Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Teniposide/Vincristine, CHVMP/VCR-BLEO 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (5)

Antineoplastic Combined Chemotherapy ProtocolsBleomycinCyclophosphamideTeniposide
DoxorubicinDoxorubicin HydrochloridePrednisoneVincristine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1994
Highly Cited
1994
Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
BACKGROUND Older patients with non-Hodgkin's lymphoma (NHL) display a poorer response to chemotherapy and a significantly higher… 
1994
1994
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
In the EORTC lymphoma cooperative group, a randomized phase III study was done for patients with stage II, III, IV intermediate… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)